Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer. Parikh NR, Chang EM, Nickols NG, Rettig MB, et al. Int J Radiat Oncol Biol Phys 2020 Jun 13. pii: S0360-3016(20)31250.

Read + Share

Amedeo Smart

Independent Medical Education

Parikh NR, Chang EM, Nickols NG, Rettig MB, et al. Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer. Int J Radiat Oncol Biol Phys 2020 Jun 13. pii: S0360-3016(20)31250.
PMID: 32544574